Novartis to Buy Regulus Therapeutics for up to $1.7 Billion
April 30 (Reuters) - Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Shares of Regulus surged nearly 130% to $7.74 in morning trading.
Under terms of the deal, Novartis would pay Regulus upfront $7 per share in cash, or about $800 million, which represents a premium of about 108% to the stock's last closing price.
Regulus is also eligible to receive an additional $7 per share contingent upon certain regulatory milestones for the kidney disease drug, farabursen.
The deal is expected to be completed in the second half of this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10